Compare PAHC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | DNTH |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2014 | N/A |
| Metric | PAHC | DNTH |
|---|---|---|
| Price | $38.78 | $50.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $31.25 | ★ $68.88 |
| AVG Volume (30 Days) | 202.2K | ★ 770.6K |
| Earning Date | 02-05-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ 288.74 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $1,399,676,000.00 | $3,078,000.00 |
| Revenue This Year | $15.34 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | $23.66 | ★ N/A |
| Revenue Growth | ★ 33.72 | N/A |
| 52 Week Low | $16.16 | $13.37 |
| 52 Week High | $46.42 | $54.00 |
| Indicator | PAHC | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 66.34 |
| Support Level | $38.29 | $50.00 |
| Resistance Level | $39.91 | $52.02 |
| Average True Range (ATR) | 1.44 | 3.07 |
| MACD | -0.06 | 0.91 |
| Stochastic Oscillator | 16.60 | 81.15 |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.